Eloralintide And Tirzepatide
AMPLIFY-1
Eli Lilly · Phase 3 · Not yet recruiting · Enrollment 2115
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| EloraTZP Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| EloraTZP Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| EloraTZP Dose 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| EloraTZP Dose 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| EloraTZP Dose 5 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Tirzepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Eloralintide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |